Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: Towards personalized medicine

Pharmacogenomics

Volumn 14, Issue 4, 2013, Pages 425-444

  Umićević Mirkov, Maša ^a   Coenen, Marieke J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

disease modifying antirheumatic drugs; DMARDs; pharmacogenetics; rheumatoid arthritis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABATACEPT; ADALIMUMAB; AURANOFIN; AUROLATE; AUROTHIOMALATE; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; DIHYDROOROTATE DEHYDROGENASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MYOCRYSINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SODIUM PROTON EXCHANGE PROTEIN 1; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2) GENE; AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; CORNEA DISEASE; CROHN DISEASE; CYTOCHROME P450 1A2 GENE; CYTOCHROME P450 2C19 GENE; DIARRHEA; DIHYDROOROTATE DEHYDROGENASE GENE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GINGIVA HYPERPLASIA; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; INTERLEUKIN 1 GENE; INTERLEUKIN 6 GENE; KIDNEY FAILURE; KIDNEY INJURY; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOUTH ULCER; MULTIDRUG RESISTANCE PROTEIN 1 GENE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM PROTON EXCHANGE PROTEIN 1 GENE; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOCYTOPENIA; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUMOR LYSIS SYNDROME; TUMOR NECROSIS FACTOR ALPHA GENE; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; GENETIC MARKERS; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; PHARMACOGENETICS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 84874635825     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.22     Document Type: Review

References (161)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358(9285), 903-911 (2001
2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 11(3), 229 (2009
3. Gonzalez A, Maradit Kremers H, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 56(11), 3583-3587 (2007
4. Schipper LG, Vermeer M, Kuper HH et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: A study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann. Rheum. Dis. 71(6), 845-850 (2012
5. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010
6. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64(5), 625-639 (2012
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44-48 (1995
8. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995
9. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370(9602), 1861-1874 (2007
10. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst. Rev. 1, CD006356 (2007
11. Van Vollenhoven RF. Treatment of rheumatoid arthritis: State of the art 2009. Nat. Rev. Rheumatol. 5(10), 531-541 (2009
12. Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull. NYU Hosp. Jt Dis. 66(3), 210-215 (2008
13. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21(5 Suppl. 31), S179-185 (2003
14. Salliot C, Van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann. Rheum. Dis. 68(7), 1100-1104 (2009
15. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006
16. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375-382 (2008
17. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology 46(10), 1520-1524 (2007
18. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 9(4), 439-451 (2008
19. Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 7(6), 404-407 (2007
20. Hayashi H, Tazoe Y, Tsuboi S et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet. doi:10.2133/ dmpk.DMPK-12-NT-038 (2012) (Epub ahead of print
21. Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11), 733-739 (2004
22. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: A study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64(11), 1057-1068 (2008
23. Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24(5), 546-554 (2006
24. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006
25. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54(10), 3095-3103 (2006
26. Kato T, Hamada A, Mori S, Saito H. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet. 27(2), 192-199 (2012
27. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 48(6), 613-617 (2009
28. Plaza-Plaza JC, Aguilera M, Canadas-Garre M et al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS 16(11), 589-595 (2012
29. Pawlik A, Wrzesniewska J, Fiedorowicz- Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42(9), 496-503 (2004
30. Drozdzik M, Rudas T, Pawlik A et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62(11), 933-937 (2006
31. Sharma S, Das M, Kumar A et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet. Genomics 18(12), 1041-1049 (2008
32. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11(2), 163-175 (2010
33. Stamp LK, Chapman PT, O'Donnell JL et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet. Genomics 20(6), 367-376 (2010
34. Ranganathan P, Culverhouse R, Marsh S et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35(4), 572-579 (2008
35. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. doi:10.1038/tpj.2012.7 (2012) (Epub ahead of print
36. Cronstein BN. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57(2), 163-172 (2005
37. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36(3), 539-545 (2009
38. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J. Inherit. Metab. Dis. 19(5), 589-594 (1996
39. Chango A, Boisson F, Barbe F et al. The effect of 677C->T and 1298A->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br. J. Nutr. 83(6), 593-596 (2000
40. Trembath D, Sherbondy AL, Vandyke DC et al. Analysis of select folate pathway genes, PAX3, and human T in a midwestern neural tube defect population. Teratology 59(5), 331-341 (1999
41. Owen SA, Lunt M, Bowes J et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: Analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. doi:10.1038/tpj.2011.42 (2011) (Epub ahead of print
42. Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: A meta-analysis. Pharmacogenet. Genomics 22(2), 117-133 (2012
43. Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: A meta-analysis. Clin. Drug Investig. 30(2), 101-108 (2010
44. Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr. Opin. Rheumatol. 23(3), 282-287 (2011
45. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350(21), 2167-2179 (2004
46. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10(2), 303-309 (2009
47. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68(8), 1367-1368 (2009
48. O'Doherty C, Schnabl M, Spargo L et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics 13(12), 1427-1434 (2012
49. Kalgutkar AS, Nguyen HT, Vaz AD et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726. mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 31(10), 1240-1250 (2003
50. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 64(9), 871-876 (2008
51. Wiese MD, Schnabl M, O'Doherty C et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res. Ther. 14(4), R163 (2012
52. Gadangi P, Longaker M, Naime D et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156(5), 1937-1941 (1996
53. Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr. Drug Metab. 9(6), 532-537 (2008
54. Tanaka E, Taniguchi A, Urano W et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol. 29(12), 2492-2499 (2002
55. Wadelius M, Stjernberg E, Wiholm BE, Rane A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10(1), 35-41 (2000
56. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57(1), 117-145 (2005
57. Pawlik A, Kurzawski M, Gornik W, Dabrowska-Zamojcin E, Drozdzik M. 677C > T and 1298A > C MTHFR polymorphisms affect arechin treatment outcome in rheumatoid arthritis. Pharmacol. Rep. 59(6), 721-726 (2007
58. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001
59. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000
60. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22), 1594-1602 (2000
61. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics R. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 56(1), 13-20 (2007
62. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23(6), 795-800 (2005
63. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab. results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22-32 (2010
64. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159-167 (2006
65. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract. Res. Clin. Rheumatol. 25(4), 549-567 (2011
66. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10(3), 308-315 (2010
67. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14), 1460-1468 (2011
68. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 50(8), 1445-1452 (2011
69. Cuchacovich M, Soto L, Edwardes M et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35(6), 435-440 (2006
70. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)- stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol. 113(3), 401-406 (1998
71. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: A meta-analysis. Rheumatol. Int. 27(2), 157-161 (2006
72. O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: A systematic review and meta-analysis. Pharmacogenomics J. 9(3), 161-167 (2009
73. Pavy S, Toonen EJ, Miceli-Richard C et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: Systematic review and meta-analysis. Ann. Rheum. Dis. 69(6), 1022-1028 (2010
74. Lee YH, Ji JD, Bae SC, Song GG. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: A metaanalysis update. J. Rheumatol. 37(4), 740-746 (2010
75. Cui J, Saevarsdottir S, Thomson B et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 62(7), 1849-1861 (2010
76. Plant D, Prajapati R, Hyrich KL et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 64(3), 665-670 (2012
77. Krintel SB, Palermo G, Johansen JS et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22(8), 577-589 (2012
78. Umićević Mirkov M, Cui J, Vermeulen SH et al. Genome-wide association analysis of anti-TNF drug response in rheumatoid arthritis patients. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202405 (2012) (Epub ahead of print
79. Liu C, Batliwalla F, Li W et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9-10), 575-581 (2008
80. Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: A prospective case-only study. Arthritis Res. Ther. 12(2), R72 (2010
81. Plant D, Bowes J, Potter C et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63(3), 645-653 (2011
82. Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr. Opin. Rheumatol. 20(2), 145-152 (2008
83. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5(7), 564-576 (2006
84. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004
85. Emery P, Fleischmann R, Filipowicz- Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a Phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5), 1390-1400 (2006
86. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006
87. Fabris M, Quartuccio L, Lombardi S et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun. Rev. 11(5), 315-320 (2012
88. Robledo G, Davila-Fajardo CL, Marquez A et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 31(9), 1486-1491 (2012
89. Kastbom A, Coster L, Arlestig L et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: An observational cohort study. BMJ Open 2(5), e001524 (2012
90. Ruyssen-Witrand A, Rouanet S, Combe B et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 71(6), 875-877 (2012
91. Fabris M, Quartuccio L, Vital E et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum. 65(1), 88-97 (2012
92. Daien CI, Fabre S, Rittore C et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79(5), 471-475 (2012
93. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12), 2196-2204 (1998
94. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 22(6), 396-402 (1992
95. Cantagrel A, Navaux F, Loubet-Lescoulie P et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum. 42(6), 1093-1100 (1999
96. Camp NJ, Cox A, Di Giovine FS, McCabe D, Rich W, Duff GW. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun. 6(6), 467-471 (2005
97. Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther. Clin. Risk Manag. 4(4), 767-775 (2008
98. Wang J, Bansal AT, Martin M et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. doi:10.1038/ tpj.2012.8 (2012) (Epub ahead of print
99. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953-963 (2008
100. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007
101. Fransen J, Kooloos WM, Wessels JA et al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 13(9), 1087-1094 (2012
102. James HM, Gillis D, Hissaria P et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol. 35(4), 562-571 (2008
103. Dervieux T, Wessels JA, Kremer JM et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet. Genomics 22(1), 1-9 (2012
104. Coulthard LR, Taylor JC, Eyre S et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann. Rheum. Dis. 70(1), 98-103 (2011
105. Potter C, Cordell HJ, Barton A et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann. Rheum. Dis. 69(7), 1315-1320 (2010
106. Hess A, Axmann R, Rech J et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc. Natl Acad. Sci. USA 108(9), 3731-3736 (2011
107. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3), 183-190 (2002
108. Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 8(11), 1551-1559 (2007
109. Taniguchi A, Urano W, Tanaka E et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genomics 17(6), 383-390 (2007
110. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44(11), 2525-2530 (2001
111. Weisman MH, Furst DE, Park GS et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 54(2), 607-612 (2006
112. Xiao H, Xu J, Zhou X et al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin. Exp. Rheumatol. 28(5), 728-733 (2010
113. Choe JY, Lee H, Jung HY, Park SH, Bae SC, Kim SK. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol. Int. 32(6), 1837-1842 (2012
114. Caliz R, Del Amo J, Balsa A et al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand. J. Rheumatol. 41(1), 10-14 (2012
115. Berkun Y, Levartovsky D, Rubinow A et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 63(10), 1227-1231 (2004
116. Hughes LB, Beasley TM, Patel H et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65(9), 1213-1218 (2006
117. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med. 11(5), 593-600 (2003
118. Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin. Exp. Rheumatol. 27(3), 499-502 (2009
119. Mena JP, Salazar-Paramo M, Gonzalez-Lopez L et al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: Implication with elevation of transaminases. Pharmacogenomics J. 11(4), 287-291 (2011
120. Tasbas O, Borman P, Gurhan Karabulut H, Tukun A, Yorgancioglu R. The frequency of A1298C and C677T polymorphisms of the methylentetrahydrofolate gene in Turkish patients with rheumatoid arthritis: Relationship with methotrexate toxicity. Open Rheumatol. J. 5, 30-35 (2011
121. Iannaccone CK, Lee YC, Cui J et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology 50(1), 40-46 (2011
122. Sharma S, Das M, Kumar A et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet. Genomics 19(10), 823-828 (2009
123. Jekic B, Lukovic L, Bunjevacki V et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur. J. Clin. Pharmacol. doi:10.1007/s00228-012-1341-3 (2012) (Epub ahead of print
124. Berkun Y, Abou Atta I, Rubinow A et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J. Rheumatol. 34(8), 1664-1669 (2007
125. Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology 47(8), 1156-1159 (2008
126. van der Straaten RJ, Wessels JA, de Vries- Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 8(2), 141-150 (2007
127. Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J. Clin. Pharm. Ther. 34(3), 355-361 (2009
128. Rizzo R, Rubini M, Govoni M et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet. Genomics 16(9), 615-623 (2006
129. Baricordi OR, Govoni M, Rizzo R, Trotta F. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment. Ann. Rheum. Dis. 66(8), 1125-1126 (2007
130. Stamp LK, O'Donnell JL, Chapman PT et al. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 154-155 (2009
131. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 44(4), 547-552 (2005
132. Maxwell JR, Potter C, Hyrich KL et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum. Mol. Genet. 17(22), 3532-3538 (2008
133. Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsanopoulou AI, Drosos AA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology 46(6), 1034-1035 (2007
134. Miceli-Richard C, Comets E, Verstuyft C et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann. Rheum. Dis. 67(4), 478-484 (2008
135. Vasilopoulos Y, Bagiatis V, Stamatopoulou D et al. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis. Clin. Exp. Rheumatol. 29(4), 701-704 (2011
136. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48(7), 1849-1852 (2003
137. Fonseca JE, Carvalho T, Cruz M et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann. Rheum. Dis. 64(5), 793-794 (2005
138. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 46(1), 93-96 (2007
139. Stojanovic S, Jevtovic-Stoimenov T, Stankovic A et al. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept]. Srp. Arh. Celok. Lek. 139(11-12), 784-789 (2011
140. Balog A, Klausz G, Gal J et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71(5), 274-280 (2004
141. Guis S, Balandraud N, Bouvenot J et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 57(8), 1426-1430 (2007
142. Marotte H, Pallot-Prades B, Grange L et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann. Rheum. Dis. 65(3), 342-347 (2006
143. Criswell LA, Lum RF, Turner KN et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50(9), 2750-2756 (2004
144. Padyukov L, Lampa J, Heimburger M et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62(6), 526-529 (2003
145. Ongaro A, De Mattei M, Pellati A et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol. Int. 28(9), 901-908 (2008
146. Cuchacovich M, Ferreira L, Aliste M et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33(4), 228-232 (2004
147. Pinto JA, Rego I, Rodriguez-Gomez M et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 35(1), 177-178 (2008
148. Fabris M, Di Poi E, Sacco S, Damante G, Sinigaglia L, Ferraccioli G. [TNF- alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-alpha agents: Preliminary results]. Reumatismo 54(1), 19-26 (2002
149. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 60(8), 2541-2542 (2009
150. Schotte H, Schluter B, Drynda S et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4), 575-581 (2005
151. Martinez A, Salido M, Bonilla G et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 50(4), 1077-1082 (2004
152. Potter C, Hyrich KL, Tracey A et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 69-74 (2009
153. Morales-Lara MJ, Canete JD, Torres-Moreno D et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79(6), 591-596 (2012
154. Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B, Schaeverbeke T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin. Exp. Rheumatol. 26(2), 340-342 (2008
155. Toonen EJ, Coenen MJ, Kievit W et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 67(8), 1174-1177 (2008
156. Canete JD, Suarez B, Hernandez MV et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68(10), 1547-1552 (2009
157. Tsukahara S, Ikari K, Sato E et al. A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(12), 1791-1792 (2008
158. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 52(9), 2693-2696 (2005
159. Kastbom A, Bratt J, Ernestam S et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56(2), 448-452 (2007
160. Okuyama A, Nagasawa H, Suzuki K et al. Fcgamma receptor IIIB polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(2), 299-304 (2011
161. Tan RJ, Gibbons LJ, Potter C et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 69(6), 1029-1035 (2010